Personal Information
Unternehmen/Arbeitsplatz
Paris Area, France France
Beruf
Chef de service en Oncologie Medicale (head of medical oncology) chez Groupe Hospitalier Paris Saint Joseph
Branche
Medical / Health Care / Pharmaceuticals
Info
Prof Eric Raymond is consultant, head of medical oncology at the Paris Saint-Joseph Hospital.
Eric Raymond is board certified MD specialized in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He has been appointed as Chef de Clinique in Paris 6 Curie University with Prof. A. de Gramont for two years before undertaking a 2 year post-doctoral fellowship with Daniel D. Von Hoff at the Cancer Therapy and Research Center and Institute for Drug Development at the University of Texas in San Antonio, USA, Then, Eric Raymond undertook clinical and translational research in...
Tags
cancer
immunotherapy
hepatocellular carcinoma
antiangiogenic agent
targeted therapy
new drugs
resistance to anti-angiogenic drug
neuroendocrine tumors
hepatocarcinoma
covid-19
targeted agents
sunitinib
vegfr
tgf-beta
drug development
oncologie
oncology
pancreatic adenocarcinoma
cancer du colon
angiogenesis
pancreas
resistance to chemotherapy
resistance to immunotherapy
pnet
targeted agent
hépatocarcinome
new drug
tepotinib
c-met
pandemic
oncologist
covid
novel targets
medical oncology
octobre rose
lingerie
cancer du sein
car-t cell
hcc
chirurgie
immunotherapie
chimiotherapie
pdl1
pd1
pdgfr
bevacizumab
tumeur neuroendocrine
cell signaling
squamous cell carcinoma
anal cancer
tissue slicer
transgenic mice
leukemia
resistance to radiotherapy
mtor
chemotherapy
liver metastases
clinical trial
phase 1
second line
hgf
combination therapy
sorafenib
new target
fgfr4
healthcare
moratlity
outbreak
cancer mortality
hospital managment
cancer therapy
prevention
primary liver malignancy
liver cancer
yvon taillandier
relations franco chinoises
maladies carciovasculaires
cancérologie
hématologie
research
genetics
inca
acreditation
inssurance
microenvironment
biomarkers
novel drugs
vegfr inhibitors
tgf-beta inhibitor
met inhibitor
brca
treatment of pancreatic cancer
parp inhibitor
tumor resistance
hypoxia
hif1-alpha
patient selection
pharmacodynamic
pharmacokinetic
methodology
pf-03084014
head & neck cancer
cancer research
cell lines
human model
notch
murine model
danse
smoothies
recettes
coiffure
maquillage
saint-joseph
sophrologie
manucure
conditional survival
cancer breast
cancer survival
risk management
biopsy
cholangiocarcinoma
pricing medicine
toxicity
safety
solid tumor
hormonothérapie
intervention chirurgicale
therapie ciblee
humanized hospital
rehabilitation
prehabilitation
hormonotherapy
interventional radiology
surgery
fgf19
met-inhibitor
nab-paclitaxel
folfirinox
locally advanced
borderline operable
gemcitabine
multidisciplinarité
chimioembolisation
carcinose
cancer du rectum
intrapéritonéale
pdgf
vegf
bio marqueurs sanguins
cancer du foie
cancer du rein
immunotherpy
genetic background
vaccination
hpv18
hpv16
imaging
immunodeficiency
human immunodeficiency virus
prognostic factor
pet-scaning
hiv
first line
suntinib
pancreatic
phase 4
ex vivo models
mouse experiments
antiangiogenics
preclinical models
biotechnoligy
transcription
nut
otx-015
lymphoma
jq1
breast cancer
neuroblastoma
prostate cancer
bromodomain inhibitor
otx015
nmc
transcription reader
bromodomain
tivantinib
crizotinib
resistance to targeted agent
her3
her2
precision medicine
lanreotide
everolimus
anti-oncogene
men1
somatuline
net
checkpoint inhibitor
signaling inhibitors
vhl
endocrine malignancies
somatostatin receptor
ssa
multimodality therapy
liver-directed therapy
galunisertib
small molecule
translational research
ipilimumab
galunisetib
innovative therapy
nivolumab
blu-554
regorafenib
Mehr anzeigen
- Präsentationen
- Dokumente
- Infografiken